Metabolic impact of saffron and crocin: an updated systematic and meta-analysis of randomised clinical trials

Arch Physiol Biochem. 2022 Jun;128(3):666-678. doi: 10.1080/13813455.2020.1716020. Epub 2020 Feb 4.

Abstract

The present systematic and meta-analysis study was designed to show the protective impact of saffron and crocin supplementation on hyperlipidaemia and hyperglycaemia in randomised and clinical trials (RCTs). A pooled analysis using a model for random-effects showed that HDL-C levels were 0.21 fold higher in the saffron and 0.01 fold higher in the crocin group than placebo. LDL-C levels in the saffron group reduced by 0.51 and 0.04 fold in the crocin group versus the placebo. Moreover, TC levels in the saffron group were 0.19 lower and 0.11 fold lower in crocin group than in the placebo group. TG level in saffron group was 0.04 lower and 0.02 fold lower in crocin than the control group. The blood glucose levels did not significantly differ from the control group. This study suggests that saffron and crocin may modulate the serum lipid profile in patient with metabolic disorders.

Keywords: HDL; LDL; Saffron; cholesterol; crocin; glucose; triglyceride.

Publication types

  • Meta-Analysis

MeSH terms

  • Carotenoids / pharmacology
  • Carotenoids / therapeutic use
  • Crocus*
  • Humans
  • Hyperlipidemias* / drug therapy
  • Randomized Controlled Trials as Topic

Substances

  • Carotenoids
  • crocin